Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

34,100

Employees34,100

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

34,100

Employees34,100

BMY Key Statistics

Market cap

100.16B

Market cap100.16B

Price-Earnings ratio

-11.12

Price-Earnings ratio-11.12

Dividend yield

4.92%

Dividend yield4.92%

Average volume

16.88M

Average volume16.88M

High today

$50.09

High today$50.09

Low today

$49.06

Low today$49.06

Open price

$49.19

Open price$49.19

Volume

14.24M

Volume14.24M

52 Week high

$63.33

52 Week high$63.33

52 Week low

$39.35

52 Week low$39.35

BMY News

Simply Wall St 17h

Bristol-Myers Squibb Gains FDA Approval To Simplify Camzyos Monitoring Process

recently announced an update from the FDA on CAMZYOS®, focusing on simplified treatment protocols and expanded patient eligibility, as well as an FDA approval f...

TipRanks 4d

Sell Rating for Bristol-Myers Squibb Due to Camzyos Trial Failure and Revenue Pressures

Analyst Terence Flynn of Morgan Stanley reiterated a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $36.00. Terence...

TipRanks 4d

Bristol-Myers Squibb: Hold Rating Amid Mixed Financial Signals and Future Prospects

Wells Fargo analyst Mohit Bansal has maintained their neutral stance on BMY stock, giving a Hold rating today. Mohit Bansal’s rating is based on several factor...

Analyst ratings

77%

of 26 ratings

Buy

19.2%

Hold

76.9%

Sell

3.8%